FDA COST-EFFECTIVENESS REGS COULD BE TAILORED TO SOPHISTICATION OF AUDIENCE; FTC STAFFER SKEPTICAL ABOUT NEED FOR WELL-CONTROLLED PE TRIALS
Executive Summary
FDA is considering a regulatory approach to cost-effectiveness claims that would permit different types of communications to different types of customers.